Chimerix, Inc. (NASDAQ:CMRX - Get Free Report)'s stock price hit a new 52-week high during trading on Thursday . The stock traded as high as $8.47 and last traded at $8.46, with a volume of 118514429 shares traded. The stock had previously closed at $4.96.
Analyst Upgrades and Downgrades
A number of research firms recently issued reports on CMRX. Jefferies Financial Group reaffirmed a "hold" rating and issued a $8.50 target price (down previously from $10.00) on shares of Chimerix in a research note on Wednesday. Wedbush reaffirmed a "neutral" rating and issued a $8.55 target price (up previously from $7.00) on shares of Chimerix in a research note on Wednesday. Finally, HC Wainwright reaffirmed a "neutral" rating and issued a $8.55 target price (down previously from $11.00) on shares of Chimerix in a research note on Wednesday.
View Our Latest Report on Chimerix
Chimerix Stock Performance
The business has a 50 day moving average of $4.34 and a 200-day moving average of $2.32. The stock has a market cap of $758.16 million, a PE ratio of -8.97 and a beta of 0.32.
Insider Buying and Selling at Chimerix
In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of the business's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the transaction, the chief executive officer now directly owns 609,603 shares in the company, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last three months, insiders sold 20,760 shares of company stock worth $91,175. Insiders own 13.10% of the company's stock.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the business. Bender Robert & Associates acquired a new position in Chimerix in the 4th quarter valued at $37,000. Susquehanna Fundamental Investments LLC acquired a new position in Chimerix in the 4th quarter valued at $59,000. Jane Street Group LLC acquired a new position in Chimerix in the 4th quarter valued at $62,000. Diadema Partners LP acquired a new position in Chimerix in the 4th quarter valued at $101,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Chimerix during the 4th quarter worth $130,000. 45.42% of the stock is currently owned by institutional investors and hedge funds.
About Chimerix
(
Get Free Report)
Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.
Recommended Stories
Before you consider Chimerix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chimerix wasn't on the list.
While Chimerix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
